2022
Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania
Zhu J, Lyatuu G, Sudfeld CR, Kiravu A, Sando D, Machumi L, Minde J, Chisonjela F, Cohen T, Menzies NA. Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania. The Lancet Global Health 2022, 10: e1646-e1654. PMID: 36240830, PMCID: PMC9553191, DOI: 10.1016/s2214-109x(22)00372-2.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyCD4 cell countAntiretroviral therapyCell countART cohortAverage CD4 cell countHigher CD4 cell countsLarge HIV treatment programHealth impactsTuberculosis preventive treatmentHIV treatment programsLifetime costsIncremental lifetime costLifetime health benefitsCourse of infectionGreater health gainsLong-term healthART initiationTreat guidelinesHIV cohortPreventive therapyTuberculosis riskUS National InstitutesHIV programsSubgroup analysis
2014
Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach
Langley I, Lin HH, Egwaga S, Doulla B, Ku CC, Murray M, Cohen T, Squire SB. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. The Lancet Global Health 2014, 2: e581-e591. PMID: 25304634, DOI: 10.1016/s2214-109x(14)70291-8.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioHigh incremental costIncremental costLED fluorescence microscopyCost-effectiveness ratioPay thresholdsFull rolloutContext of TanzaniaCost-effective optionHealth policy formulationPolicy formulationDifferent diagnostic optionsIntegrated modelling approachModelling approachAdditional costHealth systemCostAlternative diagnosticsIntegrated modelXpert MTB/RIFPopulation effectsMTB/RIFPresumptive tuberculosis casesWillingnessUse of Xpert
2012
The impact of new tuberculosis diagnostics on transmission: why context matters
Lin HH, Dowdy D, Dye C, Murray M, Cohen T. The impact of new tuberculosis diagnostics on transmission: why context matters. Bulletin Of The World Health Organization 2012, 90: 739-747. PMID: 23109741, PMCID: PMC3471051, DOI: 10.2471/blt.11.101436.Peer-Reviewed Original ResearchConceptsNew tuberculosis diagnosticsNew diagnostic toolsPatient lossHuman immunodeficiency virus (HIV) infectionTuberculosis diagnosticsSmear-negative pulmonary tuberculosisDiagnostic toolImmunodeficiency virus infectionTreatment success rateSmear-negative casesIncidence of tuberculosisEpidemiology of tuberculosisPatient defaultPulmonary tuberculosisTuberculosis careDiagnostic pathwayTuberculosis transmissionSymptomatic individualsVirus infectionSmear microscopyTuberculosisAnnual declineDiagnosisAbsolute changeSuccess rateMultidrug Resistance Among New Tuberculosis Cases
Hedt BL, van Leth F, Zignol M, Cobelens F, van Gemert W, Nhung NV, Lyepshina S, Egwaga S, Cohen T. Multidrug Resistance Among New Tuberculosis Cases. Epidemiology 2012, 23: 293-300. PMID: 22249242, PMCID: PMC3276714, DOI: 10.1097/ede.0b013e3182459455.Peer-Reviewed Original Research